ProMeris

RSS

Withdrawn

This medicine's authorisation has been withdrawn

metaflumizone
MedicineVeterinaryWithdrawn

Danish is available via eTranslation, the European Commission's machine translation service.

Translate to Danish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for ProMeris has been withdrawn at the request of the marketing authorisation holder.

български (BG) (217.29 KB - PDF)

Vis

español (ES) (192.56 KB - PDF)

Vis

čeština (CS) (217.67 KB - PDF)

Vis

dansk (DA) (191.94 KB - PDF)

Vis

Deutsch (DE) (193.36 KB - PDF)

Vis

eesti (ET) (191.37 KB - PDF)

Vis

ελληνικά (EL) (219.08 KB - PDF)

Vis

français (FR) (193.21 KB - PDF)

Vis

italiano (IT) (191.59 KB - PDF)

Vis

latviešu (LV) (213.28 KB - PDF)

Vis

lietuvių (LT) (214.74 KB - PDF)

Vis

magyar (HU) (212.15 KB - PDF)

Vis

Malti (MT) (218.75 KB - PDF)

Vis

Nederlands (NL) (191.68 KB - PDF)

Vis

polski (PL) (216.46 KB - PDF)

Vis

português (PT) (192.4 KB - PDF)

Vis

română (RO) (214.2 KB - PDF)

Vis

slovenčina (SK) (215.86 KB - PDF)

Vis

slovenščina (SL) (208.53 KB - PDF)

Vis

suomi (FI) (191.92 KB - PDF)

Vis

svenska (SV) (191.72 KB - PDF)

Vis

Product information

български (BG) (389.52 KB - PDF)

Vis

español (ES) (328.73 KB - PDF)

Vis

čeština (CS) (374.1 KB - PDF)

Vis

dansk (DA) (330.12 KB - PDF)

Vis

Deutsch (DE) (340.98 KB - PDF)

Vis

eesti (ET) (336.16 KB - PDF)

Vis

ελληνικά (EL) (400.6 KB - PDF)

Vis

français (FR) (342.69 KB - PDF)

Vis

italiano (IT) (310.69 KB - PDF)

Vis

latviešu (LV) (368.86 KB - PDF)

Vis

lietuvių (LT) (376.46 KB - PDF)

Vis

magyar (HU) (368.57 KB - PDF)

Vis

Malti (MT) (376.05 KB - PDF)

Vis

Nederlands (NL) (331.24 KB - PDF)

Vis

polski (PL) (391.6 KB - PDF)

Vis

português (PT) (331.45 KB - PDF)

Vis

română (RO) (368.38 KB - PDF)

Vis

slovenčina (SK) (386.11 KB - PDF)

Vis

slovenščina (SL) (371.43 KB - PDF)

Vis

suomi (FI) (337.57 KB - PDF)

Vis

svenska (SV) (330.13 KB - PDF)

Vis

Íslenska (IS) (332.3 KB - PDF)

Vis

norsk (NO) (340.4 KB - PDF)

Vis
Latest procedure affecting product information:IB/0012
08/07/2015

български (BG) (190.37 KB - PDF)

Vis

español (ES) (144.19 KB - PDF)

Vis

čeština (CS) (184.81 KB - PDF)

Vis

dansk (DA) (144.38 KB - PDF)

Vis

Deutsch (DE) (146.91 KB - PDF)

Vis

eesti (ET) (144.06 KB - PDF)

Vis

ελληνικά (EL) (186.84 KB - PDF)

Vis

français (FR) (141.5 KB - PDF)

Vis

italiano (IT) (144.6 KB - PDF)

Vis

latviešu (LV) (189.21 KB - PDF)

Vis

lietuvių (LT) (179.82 KB - PDF)

Vis

magyar (HU) (175.56 KB - PDF)

Vis

Malti (MT) (198.96 KB - PDF)

Vis

Nederlands (NL) (141.54 KB - PDF)

Vis

polski (PL) (163.63 KB - PDF)

Vis

português (PT) (144.35 KB - PDF)

Vis

română (RO) (142.48 KB - PDF)

Vis

slovenčina (SK) (181.1 KB - PDF)

Vis

slovenščina (SL) (174.66 KB - PDF)

Vis

suomi (FI) (144.95 KB - PDF)

Vis

svenska (SV) (141.76 KB - PDF)

Vis

Íslenska (IS) (141.82 KB - PDF)

Vis

norsk (NO) (141.71 KB - PDF)

Vis

Product details

Name of medicine
ProMeris
Active substance
metaflumizone
International non-proprietary name (INN) or common name
metaflumizone
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QP53AX25

Pharmacotherapeutic group

Ectoparasiticides for topical use, incl. insecticides

Therapeutic indication

Treatment and prevention of flea infestations (Ctenocephalides canis and C. felis) in cats. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).

Authorisation details

EMA product number
EMEA/V/C/000107
Marketing authorisation holder
Pfizer Limited 

Pfizer Limited
Ramsgate Road
Sandwich
Kent CT13 9NJ
United Kingdom

Marketing authorisation issued
19/12/2006
Revision
8

Assessment history

This page was last updated on

Share this page